Consulta Pública da ANS avalia cobertura obrigatória de cloridrato de ponatinibe, indicado para o tratamento de resgate de pacientes com leucemia mieloide crônica com falha ou intolerância aos inibidores de tirosina quinase de segunda geração1 SÃO PAULO, 17 de maio de 2023 /PRNewswire/ –…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.